Share This Author
Incidence of amyotrophic lateral sclerosis in Europe
- G. Logroscino, B. Traynor, E. Beghi
- MedicineJournal of Neurology, Neurosurgery & Psychiatry
- 25 August 2009
Sex differences in incidence may be explained by the higher incidence of spinal onset ALS among men, and the age related disease pattern suggests that ALS occurs within a susceptible group within the population rather than being a disease of ageing.
EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force
The evidence base for the diagnosis and management of amyotrophic lateral sclerosis (ALS) is weak and needs to be strengthened, according to the authors.
Amyotrophic lateral sclerosis
The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study
- J. Phukan, M. Elamin, O. Hardiman
- Psychology, MedicineJournal of Neurology, Neurosurgery & Psychiatry
- 11 August 2011
Cognitive impairment, predominantly but not exclusively in the form executive dysfunction, is present in more than 40% of ALS patients who have no evidence of dementia, and its manifestations may be more heterogeneous than previously recognised.
ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis
The finding of seven missense mutations in 15 individuals, of whom four had familial ALS and 11 apparently 'sporadic' ALS, provides further evidence that variations in hypoxia-inducible genes have an important role in motor neuron degeneration.
Prognostic factors in ALS: A critical review
- A. Chiò, G. Logroscino, On Behalf of the Eurals Consortium
- PsychologyAmyotrophic lateral sclerosis : official…
- 1 January 2009
A systematic review of factors related to survival in ALS revealed the rate of symptom progression was revealed to be an independent prognostic factor, and these findings have relevant implications for the design of future trials.
The epidemiology of ALS: a conspiracy of genes, environment and time
The relationship between genetic and environmental risk factors is examined, and a disease model in which ALS is considered to be the result of environmental risks and time acting on a pre-existing genetic load is proposed, followed by an automatic, self-perpetuating decline to death.
Clinical diagnosis and management of amyotrophic lateral sclerosis
Optimal treatment is based on symptom management and preservation of quality of life, provided in a multidisciplinary setting, and Riluzole remains the only effective drug, and extends the average survival of patients by 3–6 months.
Controversies and priorities in amyotrophic lateral sclerosis